TRIL - Morgan Stanley reports 5.3% passive stake in Trillium Therapeutics In a regulatory filing, Morgan Stanley disclosed a 5.3% stake in Trillium Therapeutics, which represents over 780,000 shares. The filing does not allow for activism.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.